What do systematic reviews say?

HALOPERIDOL vs OTHER ANTIPSYCHOTICS

HALOPERIDOL showed no clear difference in leaving the study early compared with OTHER ANTIPSYCHOTICS (low certainty).

• Haloperidol for long‐term aggression in psychosis 2016 · Cochrane Headline outcomes only
  RR 1.37 [0.84, 2.24]
  1 study · 110 participants
  Low

HALOPERIDOL vs placebo

HALOPERIDOL showed no clear difference in leaving the study early compared with PLACEBO (moderate certainty).

• Haloperidol versus placebo for schizophrenia 2013 · Cochrane Headline outcomes only
  RR 0.54 [0.29, 1]
  8 studies · 304 participants
  Moderate

HALOPERIDOL vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

HALOPERIDOL showed no clear difference in leaving the study early ‐ Due to any reason compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).

• Haloperidol versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
  RR 0.82 [0.38, 1.77]
  11 studies · 408 participants
  Low

HALOPERIDOL vs first‐generation antipsychotics

Haloperidol showed no clear difference in leaving the study early due to any reason as a measure of overall… compared with first‐generation antipsychotics (low certainty).

• Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders 2015 · Cochrane Headline outcomes only
  RR 1.04 [0.87, 1.24]
  28 studies · 1299 participants
  Low

HALOPERIDOL vs first‐generation antipsychotics

It is very uncertain whether haloperidol changes leaving the study early due to any reason as a measure of overall… compared with first‐generation antipsychotics (very low certainty).

• Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders 2015 · Cochrane Headline outcomes only
  RR 1.02 [0.75, 1.38]
  2 studies · 137 participants
  Very low

HALOPERIDOL vs first‐generation antipsychotics

It is very uncertain whether haloperidol changes leaving the study early due to adverse events as a measure of… compared with first‐generation antipsychotics (very low certainty).

• Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders 2015 · Cochrane Headline outcomes only
  RR 1 [0.42, 2.35]
  16 studies · 640 participants
  Very low

HALOPERIDOL vs first‐generation antipsychotics

• Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 80 participants
  Low

HALOPERIDOL vs first‐generation antipsychotics

It is very uncertain whether haloperidol changes leaving the study early due to inefficacy of treatment as a measure… compared with first‐generation antipsychotics (very low certainty).

• Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders 2015 · Cochrane Headline outcomes only
  RR 0.93 [0.4, 2.16]
  13 studies · 507 participants
  Very low

Haloperidol discontinuation vs haloperidol continuation

It is very uncertain whether haloperidol discontinuation changes satisfaction with treatment: leaving the study early compared with haloperidol continuation (very low certainty).

• Haloperidol discontinuation for people with schizophrenia 2019 · Cochrane Headline outcomes only
  RR 0.13 [0.01, 2.28]
  1 study · 43 participants
  Very low